Pfizer Q2 Results Climb, Beat Estimates; Lifts Low-end Of FY22 Adj. EPS View

Drug major Pfizer Inc. reported Thursday significantly higher earnings in its second quarter, above market estimates, with an all-time high quarterly sales benefited by Biopharmaceuticals and COVID-19 vaccine. Looking ahead for fiscal 2022, the company raised the low end of adjusted earnings per share forecast, and maintained revenue view.

from RTT - Top Story https://ift.tt/8YjoiXO
via IFTTT